These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 27007006)
1. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006 [No Abstract] [Full Text] [Related]
2. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816 [TBL] [Abstract][Full Text] [Related]
3. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. Howell M; Gibb A; Radford J; Linton K Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404 [No Abstract] [Full Text] [Related]
4. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Friedberg JW; Forero-Torres A; Bordoni RE; Cline VJM; Patel Donnelly D; Flynn PJ; Olsen G; Chen R; Fong A; Wang Y; Yasenchak CA Blood; 2017 Dec; 130(26):2829-2837. PubMed ID: 29038340 [TBL] [Abstract][Full Text] [Related]
5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977 [No Abstract] [Full Text] [Related]
6. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Vinti L; Pagliara D; Buffardi S; Di Ruscio V; Stocchi F; Mariggiò E; Parasole R; Di Matteo A; Petruzziello F; Paganelli V; De Vito R; Del Bufalo F; Strocchio L; Locatelli F Pediatr Blood Cancer; 2022 Apr; 69(4):e29557. PubMed ID: 35107876 [TBL] [Abstract][Full Text] [Related]
7. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series. McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648 [No Abstract] [Full Text] [Related]
8. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant. Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999 [No Abstract] [Full Text] [Related]
9. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910 [TBL] [Abstract][Full Text] [Related]
10. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Oak E; Bartlett NL Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Uncu Ulu B; Dal MS; Yönal Hindilerden İ; Akay OM; Mehtap Ö; Büyükkurt N; Hindilerden F; Güneş AK; Yiğenoğlu TN; Başcı S; Kızıl Çakar M; Yanardağ Açık D; Korkmaz S; Ulaş T; Özet G; Ferhanoğlu B; Nalçacı M; Altuntaş F J Chemother; 2022 May; 34(3):190-198. PubMed ID: 34514960 [TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643 [No Abstract] [Full Text] [Related]
13. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD). Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Younes A Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Harker-Murray P; Mauz-Körholz C; Leblanc T; Mascarin M; Michel G; Cooper S; Beishuizen A; Leger KJ; Amoroso L; Buffardi S; Rigaud C; Hoppe BS; Lisano J; Francis S; Sacchi M; Cole PD; Drachtman RA; Kelly KM; Daw S Blood; 2023 Apr; 141(17):2075-2084. PubMed ID: 36564047 [TBL] [Abstract][Full Text] [Related]
16. Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Sawas A; Ma H; Kuruvilla J; Lue JK; Deng C; Marchi E; Montanari F; Cheng B; Savage KJ; Villa D; Crump M; Connors JM; O'Connor OA Leuk Lymphoma; 2020 Dec; 61(12):3014-3017. PubMed ID: 32720828 [No Abstract] [Full Text] [Related]
17. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725 [No Abstract] [Full Text] [Related]
18. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458 [TBL] [Abstract][Full Text] [Related]
19. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. Bartlett NL Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273 [TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient Program experience in 241 patients. Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):4-5. PubMed ID: 25768991 [No Abstract] [Full Text] [Related] [Next] [New Search]